argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
833.42
-6.86 (-0.82%)
Feb 25, 2026, 1:53 PM EST - Market open
argenx SE Revenue
argenx SE had revenue of $1.15B in the quarter ending September 30, 2025, with 95.51% growth. This brings the company's revenue in the last twelve months to $3.69B, up 93.18% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.52% growth.
Revenue (ttm)
$3.69B
Revenue Growth
+93.18%
P/S Ratio
13.89
Revenue / Employee
$2,303,490
Employees
1,599
Market Cap
51.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | -15.91M | -32.14% |
| Dec 31, 2017 | 49.50M | 31.46M | 174.30% |
| Dec 31, 2016 | 18.05M | 7.24M | 66.96% |
| Dec 31, 2015 | 10.81M | 4.30M | 66.15% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | 3.23M | 80.65% |
| Dec 31, 2012 | 4.00M | 11.07K | 0.28% |
| Dec 31, 2011 | 3.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.34B |
| Vertex Pharmaceuticals | 12.00B |
| Incyte | 5.14B |
| BeOne Medicines AG | 4.97B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.70B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
ARGX News
- 2 days ago - argenx to Present at TD Cowen 46th Annual Healthcare Conference - GlobeNewsWire
- 6 days ago - Allspring Large Cap Growth Fund Q4 2025 Performance Update - Seeking Alpha
- 9 days ago - Invesco International Growth Fund Q4 2025 Portfolio Update - Seeking Alpha
- 12 days ago - Allspring Growth Fund Q4 2025 Fund Performers And Detractors - Seeking Alpha
- 27 days ago - Artisan Global Opportunities Fund Q4 2025 Portfolio Update - Seeking Alpha
- 4 weeks ago - Prime Capital Investment Advisors, LLC Buys 266 Shares of argenx SE (ARGX) - GuruFocus
- 5 weeks ago - Independence Bank of Kentucky Buys 2 Shares of argenx SE (ARGX) - GuruFocus
- 5 weeks ago - ARGX: Wells Fargo Raises Price Target to $1317, Maintains Overweight Rating | ARGX Stock News - GuruFocus